Previous 10 | Next 10 |
2024-02-16 17:20:10 ET More on AbCellera Biologics AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Abs...
2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...
AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link tha...
2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throu...
2023-12-16 13:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the biggest stories of the year has been the rise of AI in every industry. This trend will hit biotech stocks no less than any others. Already, cutting edge healthcare stocks ...
2023-12-10 13:04:00 ET More on AbCellera Biologics, Absci, etc. AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform Certara, Inc. 2023 Q3 - Results - Earnings Call Prese...
2023-12-08 01:30:09 ET Summary AbCellera's stock has decreased by 34% since I gave it a "sell" rating in March. The company's high valuation was largely based on its success discovering the COVID antiviral bamlanivimab, which earned >$4bn revenues but has since been withdrawn f...
2023-12-07 23:39:44 ET Summary AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two drugs set for IND approval in 2025. AbCellera has...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
2024-05-08 17:30:13 ET KeyBanc analyst issues OVERWEIGHT recommendation for ABCL on May 8, 2024 02:46AM ET. The previous analyst recommendation was Overweight. ABCL was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...
2024-05-08 04:30:12 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q1 2024 Earnings Call May 07, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q1 2024 Earnings Call Tran...
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investment...